March 31, 2025 03:05 PM EDT

Vaxcyte's Phase 2 pneumococcal vaccine data disappoint Wall Street

Max Gelman

Senior Editor

Vaxcyte’s stock price $PCVX dropped by 50% on Monday after the company reported new Phase 2 data from a study evaluating an experimental pneumococcal vaccine …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Vaxcyte's Phase 2 pneumococcal vaccine data disappoint Wall Street

Max Gelman

Senior Editor

Sign up to read this article for free.

Vice President, Biology & Translational Research

Gondolabio

Palo Alto, CA, USA

Firings sweep across FDA as former leaders lament the gutting of drug agency

RFK Jr. has long criticized drug ads. He just slashed the FDA office that regulates them

‘It’ll be a challenge’: BIO chief Crowley addresses seismic FDA overhaul

Sanofi continues its bet on R&D by poaching GSK’s head of development

Big ambitions at Merck and AstraZeneca — along with a few giant pitfalls — reshape top ranks of the R&D 15

Endpoints webinar: Inside the “One Lonza” strategy: Re-engineering the future of CDMO

Vax­cyte's Phase 2 pneu­mo­coc­cal vac­cine da­ta dis­ap­point Wall Street

Senior Editor

Sign up to read this article for free.

Gondolabio

Palo Alto, CA, USA

Vaxcyte's Phase 2 pneumococcal vaccine data disappoint Wall Street